RZLT

Rezolute, Inc.

3.90 USD
-1.26 (-24.42%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rezolute, Inc. stock is up 47.17% since 30 days ago. The next earnings date is Sep 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.55% of the previous 10 June’s closed higher than May. 100% of analysts rate it a buy.

About Rezolute, Inc.

Rezolute, Inc. develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

  • Craig-Hallum
    Tue Jun 4, 08:32
    buy
    initial
  • HC Wainwright & Co.
    Wed May 22, 07:46
    buy
    confirm
  • HC Wainwright & Co.
    Thu May 16, 11:23
    buy
    confirm